There are four models in the world, and one in Nanjing

  With the Shihe Eagle Eye® tumor early screening product of Shihe Gene, only one tube of blood is needed to screen nine common cancers at one time, including lung cancer, liver cancer, and colorectal cancer;
○  The SURFSeq Q ultra-high-throughput gene sequencer from GeneMed Biotechnology can produce up to 9Tb of data per day, which is equivalent to sequencing more than 23,000 whole genomes per year.
○  Nanzhi Xinshi’s chip-based large-field-of-view hyper-constructive microscope is only the size of a power bank, but its imaging field of view can reach 7-10 times that of traditional equipment. It can be used for high-throughput observation, testing and lesion diagnosis.
○  Some institutions predict that the current total potential market size of the global genetic industry is 242.5 billion yuan, and the market size of cell therapy drugs in China will grow from 1.3 billion yuan in 2021 to 58.4 billion yuan in 2030.

○  The gene and cell technology of Jiangbei New Area has been included in the province’s first batch of future industry pilot projects for cluster development. In fact, many of the “genes” here have reached the “top” of the industry.

01There are four models in the world, and one in Nanjing○  Last October, the CEI-1® Tumor Mutation Burden Detection Kit [National Medical Device Registration No. 20233401452] was approved through the innovative medical device procedure. It can detect more than 400 genes at a time, filling the gap in domestic large-panel gene detection products. It is the only domestic “innovative” reagent product launched in 2023. So far, CEI-1 has become the only company in the tumor precision medicine industry that has two innovative NGS kit products.

Last December, the CanScan® multi-cancer early screening product independently developed by Genentech and based on MERCURY multi-omics liquid biopsy technology was recognized as a breakthrough medical device by the US FDA. Currently, there are only four multi-cancer early screening products that have obtained this certification in the world, and Genentech Eagle Eye® is the early screening product in China that covers the most cancer types and has the widest screening range.
○  Gene and cell technology has huge market potential in the field of life and health, and its emerging disruptive technologies are providing strong protection for people’s life and health.
○  Traditional methods for early cancer screening mainly include imaging examinations, tumor marker testing, tissue biopsy, etc. These methods usually have problems such as long preparation time, invasiveness, and limited accuracy.

The early cancer screening product of Shihe Eagle Eye® uses MERCURY multi-omics liquid biopsy technology. With only one tube of blood, it can screen nine common cancers including lung cancer, liver cancer, and colon cancer at one time. Once an abnormal signal is found, Shihe Eagle Eye® can also locate the specific part of the signal source, thereby greatly shortening the time and process of tumor screening.
○  “Understanding the most urgent clinical problems is always our focus during the research and development process.” Wang Xiaonan, co-founder and chief technology officer of Nanjing Shihe Gene Biotechnology Co., Ltd., said that Shihe’s products have expanded from supporting precise drug use in the late stage of cancer and early and mid-stage recurrence risk assessment to early screening, realizing a full-line layout from “early” to “late”.
○  In 2022, Genentech, together with Nanjing Jiangbei New District and Nanjing Medical University, launched the “Jinling Cohort” large-scale natural population cancer early screening charity project, which plans to provide 100,000 Nanjing citizens aged 45-75 with free physical examinations for three years, and simultaneously verify the early screening performance of Genentech Eagle Eye®. At present, the project has provided free physical examinations for 15,000 residents of Nanjing Jiangbei New District. Data so far show that Genentech Eagle Eye® has demonstrated world-leading excellent performance in the field of early screening of multiple cancers.

02 How high is “super high”?○  SURFSeq Q ultra-high throughput gene sequencer, the word “ultra-high” directly expresses the important features of this device. “In addition to the ultra-high detection data throughput, this product also has a very high sequencing accuracy of over 99.95%.” Zhou Zhiliang, president and co-founder of Zhenmai Bio, introduced that the main application scenarios of the product are large-scale scientific research projects, which have extremely high requirements for product accuracy.

  Gene sequencers, also known as DNA sequencers, are instruments that determine the base sequence, type, and quantity of DNA fragments. Globally, gene sequencing technology and products have been widely used in various medical and scientific research fields, and various application scenarios are still being developed. However, this promising track has long been dominated by overseas products.
○  12 years ago, Zhenmai Biotech started from scratch and focused on the self-development and production of gene sequencers. Gene sequencers are complex systems that cross multiple disciplines. When Zhenmai was first established, domestic products, technology accumulation, and talent chain were almost blank.
○  Today, Zhenmai Bio has become one of only three companies in the world that can produce a full array of products from low-throughput, medium-throughput, high-throughput to ultra-high-throughput.

Nanjing Zhenmai Biotechnology Co., Ltd. is Zhenmai Bio’s first location outside of its headquarters in Shenzhen. The Nanjing company serves as Zhenmai Bio’s East China R&D center, production and manufacturing center, and marketing support center.
○  “Before product development, we conducted in-depth communication on user needs, and a dedicated team was responsible for investigating a large number of user units, including enterprises and research institutions.” Zhou Zhiliang introduced that, demand-oriented, Zhenmai Bio’s products have achieved full coverage of small throughput, medium throughput, high throughput and ultra-high throughput, and different products correspond to different applications.
○  The latest SURFSeq Q ultra-high throughput gene sequencer can meet the needs of large-scale population testing, spatial genomics research, agricultural breeding, etc. Some small-scale products can meet the needs of high timeliness and flexibility such as infection testing, and the results can be obtained in 3-4 hours.
○  “This year marks the third year that Zhenmai Bio has entered the overseas market. We have established cooperation with more than 50 countries and regions around the world, and the overseas market accounts for more than 30% of our revenue.” Zhou Zhiliang said.

03″Photoelectricity” blessing, stronger in the future○  It is the size of a power bank, with a socket on the top, and can be directly connected to related devices via a data cable. This is a chip-based large-field super-microscope from Nanzhi Xinshi (Nanjing) Technology Co., Ltd., whose imaging field of view can reach 7-10 times the field of view of traditional commercial microscopes at the same resolution.
○  Nanjing Zhixinshi Technology Co., Ltd. is one of the companies incubated by Nanjing Zhi Advanced Optoelectronic Integration Technology Research Institute. The chip-based large-field-of-view meta-microscope is an industrialized product transformed from the research results of Professor Li Tao’s team at the School of Modern Engineering and Applied Sciences of Nanjing University.
○  This highly integrated chip-based super microscope has been listed as one of the important achievements and top ten advances in Chinese optics. “It is small in size and has strong imaging performance. The core imaging component is only on the scale of a ‘chip’. It can be used as an important core module and is very flexible for imaging and detection equipment in various environments, such as microendoscopy, microfluidic cell counting, pathology scanning, etc., to meet high-throughput observation and diagnosis of lesions.” Cheng Zhaoyu, general manager of Nanzhi Xinshi, introduced.